BioLargo Financials
| BLGO Stock | USD 0.29 0.01 3.33% |
With this module, you can analyze BioLargo financials for your investing period. You should be able to track the changes in BioLargo individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
BioLargo |
Understanding current and past BioLargo Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of BioLargo's financial statements are interrelated, with each one affecting the others. For example, an increase in BioLargo's assets may result in an increase in income on the income statement.
The data published in BioLargo's official financial statements typically reflect BioLargo's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving BioLargo's quantitative information. For example, before you start analyzing numbers published by BioLargo accountants, it's essential to understand BioLargo's liquidity, profitability, and earnings quality within the context of the Chemicals space in which it operates.
BioLargo Stock Summary
BioLargo competes with Asahi Kaisei, ASP Isotopes, Ganfeng Lithium, Shin-Etsu Chemical, and Lsb Industries. BioLargo, Inc. invents, develops, and commercializes various platform technologies. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California. Biolargo operates under Chemicals classification in the United States and is traded on OTC Exchange. It employs 31 people.| Instrument | USA OTC Stock View All |
| Exchange | OTCQX Exchange |
| ISIN | US09065A1007 |
| Business Address | 14921 Chestnut Street, |
| Sector | Chemicals |
| Industry | Materials |
| Benchmark | Dow Jones Industrial |
| Website | www.biolargo.com |
| Phone | 888 400 2863 |
| Currency | USD - US Dollar |
BioLargo Key Financial Ratios
BioLargo's financial ratios allow both analysts and investors to convert raw data from BioLargo's financial statements into concise, actionable information that can be used to evaluate the performance of BioLargo over time and compare it to other companies across industries.| Return On Equity | -3.63 | |||
| Return On Asset | -0.69 | |||
| Target Price | 0.29 | |||
| Number Of Employees | 31 | |||
| Beta | -0.0345 |
BioLargo Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BioLargo's current stock value. Our valuation model uses many indicators to compare BioLargo value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioLargo competition to find correlations between indicators driving BioLargo's intrinsic value. More Info.BioLargo is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value BioLargo by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for BioLargo's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.BioLargo Systematic Risk
BioLargo's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. BioLargo volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on BioLargo correlated with the market. If Beta is less than 0 BioLargo generally moves in the opposite direction as compared to the market. If BioLargo Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one BioLargo is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of BioLargo is generally in the same direction as the market. If Beta > 1 BioLargo moves generally in the same direction as, but more than the movement of the benchmark.
BioLargo January 21, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of BioLargo help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of BioLargo. We use our internally-developed statistical techniques to arrive at the intrinsic value of BioLargo based on widely used predictive technical indicators. In general, we focus on analyzing BioLargo OTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build BioLargo's daily price indicators and compare them against related drivers.
| Downside Deviation | 6.62 | |||
| Information Ratio | 0.0908 | |||
| Maximum Drawdown | 24.39 | |||
| Value At Risk | (5.26) | |||
| Potential Upside | 11.11 |
Other Information on Investing in BioLargo OTC Stock
BioLargo financial ratios help investors to determine whether BioLargo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLargo with respect to the benefits of owning BioLargo security.